About: Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid
Creator	Drebot, Michael Berry, Jody Li, Xuguang Cao, Jingxin He, Runtao Adonov, Anton Cutts, Todd Deschambaul, Yvon Grudesky, Elsie Traykova-Adonova, Maya
Source	Elsevier; Medline; PMC
abstract	Abstract The severe acute respiratory syndrome virus (SARS) is a coronavirus that instigated regional epidemics in Canada and several Asian countries in 2003. The newly identified SARS coronavirus (SARS-CoV) can be transmitted among humans and cause severe or even fatal illnesses. As preventive vaccine development takes years to complete and adverse reactions have been reported to some veterinary coronaviral vaccines, anti-viral compounds must be relentlessly pursued. In this study, we analyzed the effect of aurintricarboxylic acid (ATA) on SARS-CoV replication in cell culture, and found that ATA could drastically inhibit SARS-CoV replication, with viral production being 1000-fold less than that in the untreated control. Importantly, when compared with IFNs α and β, viral production was inhibited by more than 1000-fold as compared with the untreated control. In addition, when compared with IFNs α and β, ATA was approximately 10 times more potent than IFN α and 100 times more than interferon β at their highest concentrations reported in the literature previously. Our data indicated that ATA should be considered as a candidate anti-SARS compound for future clinical evaluation.
has issue date	2004-08-06(xsd:dateTime)
bibo:doi	10.1016/j.bbrc.2004.06.076
bibo:pmid	15249217
has license	els-covid
sha1sum (hex)	fec6b0a7e0d3af7865139dd59fa29788155eb703
schema:url	https://doi.org/10.1016/j.bbrc.2004.06.076
resource representing a document's title	Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid
has PubMed Central identifier	PMC7111066
has PubMed identifier	15249217
schema:publication	Biochemical and Biophysical Research Communications
resource representing a document's body	covid:fec6b0a7e0d3af7865139dd59fa29788155eb703#body_text
is schema:about of	named entity 'SARS-CoV' named entity 'Our' named entity 'UNTREATED' named entity 'SARS CORONAVIRUS' named entity 'CORONAVIRUS' named entity 'TRANSMITTED' named entity 'YEARS' named entity 'CONCENTRATIONS' named entity 'FOUND' named entity 'HUMANS' named entity 'STUDY' named entity 'COMPOUND' named entity 'CLINICAL EVALUATION' named entity 'TIMES' named entity 'SARS' named entity 'CONTROL' named entity 'APPROXIMATELY' named entity 'SELECTIVE' named entity 'INHIBITED' named entity 'IDENTIFIED' named entity '1000' named entity 'EFFECT' named entity 'ILLNESSES' named entity 'INHIBITION' named entity 'SARS CORONAVIRUS' named entity 'AURINTRICARBOXYLIC ACID' named entity 'MORE THAN' named entity 'REGIONAL' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'FATAL' named entity 'PREVENTIVE' named entity 'VETERINARY' named entity 'COMPARED' named entity 'ANALYZED' named entity 'CANDIDATE' named entity 'VACCINES' named entity 'ATA' named entity 'BEING' named entity 'INDICATED' named entity 'FUTURE' named entity 'THEIR' named entity 'CANADA' named entity 'SEVERE' named entity 'CELL CULTURE' named entity 'REPLICATION' named entity 'IFN' named entity 'ADVERSE REACTIONS' named entity 'CONSIDERED' named entity 'AURINTRICARBOXYLIC ACID' named entity 'COMPLETE' named entity 'PRODUCTION' named entity 'ASIAN COUNTRIES' named entity 'FOLD' named entity 'LITERATURE' named entity '100' named entity 'VIRAL' named entity 'LESS THAN' named entity 'PREVIOUSLY' named entity 'VACCINE DEVELOPMENT' named entity 'CAUSE' named entity 'NEWLY' named entity 'REPORTED' named entity 'OUR' named entity 'HIGHEST' named entity 'HAVE' named entity 'DATA' named entity 'IS A' named entity 'VIRUS' named entity 'ADDITION' named entity 'EPIDEMICS' covid:arg/fec6b0a7e0d3af7865139dd59fa29788155eb703 named entity 'compared'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software